Barclays upgrades Revvity, says stock ‘checks most of the boxes’

Barclays upgraded Revvity to Overweight from Equal Weight with a price target of $140, up from $125. The firm is more constructive on Revvity, saying the stock “checks most of the boxes” within its investment framework for how the tools and diagnostics space will unfold for the rest of the year and 2025. Barclays expects Revvity to continue to grow at the high end of the tools and diagnostics group, buoyed by life science outperforming the overall tools market and diagnostics “continuing to chug along.” Revvity shares trade at a discount to peers despite a promising fundamental profile, contends Barclays.